BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Shastri YM, Stein JM. Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening. World J Gastroenterol 2007; 13(19): 2768-2769 [PMID: 17569153 DOI: 10.3748/wjg.v13.i19.2768]
URL: https://www.wjgnet.com/1007-9327/full/v13/i19/2768.htm
Number Citing Articles
1
Claudia Sanna, Chiara Giordanino, Ilaria Giono, Claudio Barletti, Arnaldo Ferrari, Serafino Recchia, Dario Reggio, Alessandro Repici, Alessandro Ricchiuti, Mauro Salizzoni, Ileana Baldi, Giovannino Ciccone, Mario Rizzetto, Giorgio Saracco. Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Patients with Post-Liver Transplant Biliary Complications: Results of a Cohort Study with Long-Term Follow-UpGut and Liver 2011; 5(3): 328 doi: 10.5009/gnl.2011.5.3.328
2
Yogesh M. Shastri, Stefan Loitsch, Nicolas Hoepffner, Nada Povse, Ernst Hanisch, Wolfgang Rösch, Joachim Mössner, Jürgen M. Stein. Comparison of an Established Simple Office-Based Immunological FOBT With Fecal Tumor Pyruvate Kinase Type M2 (M2-PK) for Colorectal Cancer Screening: Prospective Multicenter StudyThe American Journal of Gastroenterology 2008; 103(6): 1496 doi: 10.1111/j.1572-0241.2008.01824.x
3
Lorena Bouzas, Jesús Hermida, J. Carlos Tutor. Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: Diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrationsUpsala Journal of Medical Sciences 2010; 115(2): 125 doi: 10.3109/03009730903291026
4
Y M Shastri, J M Stein. New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?British Journal of Cancer 2007; 97(11): 1595 doi: 10.1038/sj.bjc.6604039